Abstract 2132P
Background
Survivors of lung cancer (LCS) have unmet emotional, social, and physical needs regardless of stage at diagnosis or treatment types, experience decreased quality of life (QOL) and high financial toxicity (FT). The relationship between unmet needs, QOL, and FT is yet to be reported in LCS and may provide insight into potentially modifiable needs to address to improve patient reported outcomes.
Methods
We performed a cross-sectional survey to assess the physical, social, emotional, and medical needs, QOL, and FT in patients with histologically confirmed non-small cell lung cancer alive > 1 year from diagnosis. The survey consisted of an adapted needs survey, the Comprehensive Score for FT (COST), and the lung cancer specific QOL questionnaires EORTC-QLQ and EORTC-QLQ-LC13. Demographic and clinical information was obtained retrospectively by chart review. Separate multiple linear regression models, treating QOL and FT as dependent variables, were performed to assess the adjusted relationship between total number of unmet needs and type of unmet need (physical, emotional, social or medical) with QOL and FT.
Results
Of 360 LCS approached, 232 surveys were completed. The median age was 69, most were female (62%), married (71%), Caucasian (74%), and had stage III/IV lung cancer (60%). Previous/current smoking history (p=0.042) and ECOG performance status of 1 or ≥ 2 (compared to 0) (p<0.0001) were each independently associated with decreased QOL. Income < $30,000 or $30,000-75,000 (compared to >$75,000) (p<0.0001), and history of radiation therapy (p=0.023) were independently associated with increased FT. Higher total unmet needs was associated with lower QOL (p<0.0001) and increased FT (p=0.0003). Greater unmet physical (p=0.023), social (p=0.008), and medical needs (p=0.007) were associated with decreased QOL. Greater social needs were associated with increased FT (p<0.0001).
Conclusions
Unmet needs across multiple domains are associated with worse QOL and FT in LCS. Identifying specific modifiable unmet needs, such as patient symptoms, care coordination, or tobacco cessation, are needed to help identify interventions. Future studies with targeted inventions to address these unmet needs may improve QOL and FT in LCS.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
J. Feliciano.
Funding
AstraZeneca.
Disclosure
J. Feliciano: Other, Institutional, Research Grant, transitions: Bristol Myers Squibb; Other, Institutional, Research Grant, survivorship: AstraZeneca; Other, Institutional, Research Grant, 4R: Pfizer; Other, Personal, Advisory Role, consultation: Regeneron; Other, Personal, Advisory Board, diversity: Eli Lilly; Other, Personal, Advisory Role: Coherus, Genentech, AstraZeneca, Daiichi; Other, Personal, Expert Testimony: AstraZeneca. M. Turner: Other, Personal, Speaker’s Bureau: AstraZeneca, Merck, Mirati. M.L. Hsu: Other, Personal, Advisory Role: Regeneron. All other authors have declared no conflicts of interest.
Resources from the same session
2151P - Incidence patterns and clinical implications of venous thromboembolism (VTE) in patients (pts) with neuroendocrine tumors (NET)
Presenter: Jorge Hernando
Session: Poster session 07
2152P - Prognostic importance of GRIM score on sorafenib side effects, hospitalization and survival in hepatocellular cancer patients
Presenter: Duygu Ercan Uzundal
Session: Poster session 07
2153P - Circulating biomarkers to predict severe complications in cancer patients with low-risk chemotherapy-associated febrile neutropenia
Presenter: Sofía Wikström Fernandez
Session: Poster session 07
2154P - Total cholesterol as an independent prognostic factor in cancer patient survival: A single institution experience
Presenter: Maria Alameda-Guijarro
Session: Poster session 07
2156P - Use of taxanes during pregnancy: A systematic review
Presenter: Ana Ferrigno Guajardo
Session: Poster session 07
2157P - A phase II randomised controlled trial comparing the cardiotoxicity of capecitabine and S-1
Presenter: Sally Clive
Session: Poster session 07
2158P - A self-assessment survey to identify the risk of patient’s screen fail in phase I clinical trials (SCITEP trial)
Presenter: Kaissa Ouali
Session: Poster session 07
2159P - Machine learning algorithms to predict the risk of chemotherapy-related toxicity in older Asians
Presenter: Mingwei Li
Session: Poster session 07
2160P - Sociodemographic disparities associated with financial toxicity in stage IV non-small cell lung cancer survivors
Presenter: Mitchell Parma
Session: Poster session 07
2161P - Organization of hospital pharmaceutical consultations for cancer patients receiving oral anticancer drugs: A nationwide cross-sectional study
Presenter: Florian Slimano
Session: Poster session 07